Information  X 
Enter a valid email address

GlaxoSmithKline PLC (GSK)

  Print      Mail a friend       Annual reports

Tuesday 20 February, 2018

GlaxoSmithKline PLC

Director/PDMR Shareholding

RNS Number : 4137F
GlaxoSmithKline PLC
20 February 2018
 

GlaxoSmithKline plc (the 'Company')

 

Transaction notification

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms E Walmsley

b)

Position/status

Chief Executive Officer

c)

Initial notification/

amendment

Initial Notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882

 

 

 

 

b)

Nature of the transaction

The exercise of nil-cost options over Ordinary Shares granted on 11 February 2015 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.

c)

Price(s) and volume(s)


Price(s)

Volume(s)



£0.0000

12,482 (Deferred)



£0.0000

8,614 (Matching)






d)

Aggregated information


Aggregated volume Price

21,096

£0.0000

e)

Date of the transaction

2018-02-16

f)

Place of the transaction

 

n/a

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms E Walmsley

b)

Position/status

Chief Executive Officer

c)

Initial notification/

amendment

Initial Notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882

 

 

 

 

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 16 February 2018 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.

c)

Price(s) and volume(s)


Price(s)

Volume(s)



£13.1563

 5,868 (Deferred)



£13.1563

 4,050 (Matching)






d)

Aggregated information


Aggregated volume Price

9,918

£13.1563

e)

Date of the transaction

2018-02-16

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr R Connor

b)

Position/status

President, Global Manufacturing & Supply

c)

Initial notification/

amendment

Initial Notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882

 

 

 

 

b)

Nature of the transaction

The exercise of nil-cost options over Ordinary Shares granted on 11 February 2015 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.

c)

Price(s) and volume(s)


Price(s)

Volume(s)



£0.0000

9,142 (Deferred)



£0.0000

6,308 (Matching)






d)

Aggregated information


Aggregated volume Price

15,450

£0.0000

e)

Date of the transaction

2018-02-16

f)

Place of the transaction

 

n/a

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

 

a)

Name

Mr R Connor

 

b)

Position/status

President, Global Manufacturing & Supply

 

c)

Initial notification/

amendment

Initial Notification

 

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

Name

GlaxoSmithKline plc

 

b)

LEI

5493000HZTVUYLO1D793

 

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

 

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882

 

 

 

 

 

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 16 February 2018 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.

 

c)

Price(s) and volume(s)


Price(s)

Volume(s)



£13.1028

4,384 (Deferred)



£13.1200

3,026 (Matching)






d)

Aggregated information


 

Aggregated volume Price

7,410

£13.1114

 

e)

Date of the transaction

2018-02-16

 

f)

Place of the transaction

 

London Stock Exchange (XLON)

 



 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr S Dingemans

b)

Position/status

Chief Financial Officer

c)

Initial notification/

amendment

Initial Notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882

 

 

 

 

b)

Nature of the transaction

The exercise of nil-cost options over Ordinary Shares granted on 11 February 2015 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.

c)

Price(s) and volume(s)


Price(s)

Volume(s)



£0.0000

17,435 (Deferred)



£0.0000

12,030 (Matching)






d)

Aggregated information


Aggregated volume Price

29,465

£0.0000

e)

Date of the transaction

2018-02-16

f)

Place of the transaction

 

n/a

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

 

a)

Name

Mr S Dingemans

 

b)

Position/status

Chief Financial Officer

 

c)

Initial notification/

amendment

Initial Notification

 

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

Name

GlaxoSmithKline plc

 

b)

LEI

5493000HZTVUYLO1D793

 

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

 

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882

 

 

 

 

 

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 16 February 2018 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.

 

c)

Price(s) and volume(s)


Price(s)

Volume(s)



£13.1236

8,360 (Deferred)



£13.1230

5,768 (Matching)






d)

Aggregated information


 

Aggregated volume Price

14,128

£13.1233

 

e)

Date of the transaction

2018-02-16

 

f)

Place of the transaction

 

London Stock Exchange (XLON)

 



 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr N Hirons

b)

Position/status

SVP, Global Ethics and Compliance

c)

Initial notification/

amendment

Initial Notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882

 

 

 

 

b)

Nature of the transaction

The exercise of nil-cost options over Ordinary Shares granted on 11 February 2015 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.

c)

Price(s) and volume(s)


Price(s)

Volume(s)



£0.0000

6,402 (Deferred)



£0.0000

4,418 (Matching)






d)

Aggregated information


Aggregated volume Price

10,820

£0.0000

e)

Date of the transaction

2018-02-16

f)

Place of the transaction

 

n/a

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

 

a)

Name

Mr N Hirons

 

b)

Position/status

SVP, Global Ethics and Compliance

 

c)

Initial notification/

amendment

Initial Notification

 

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

Name

GlaxoSmithKline plc

 

b)

LEI

5493000HZTVUYLO1D793

 

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

 

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882

 

 

 

 

 

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 16 February 2018 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.

 

c)

Price(s) and volume(s)


Price(s)

Volume(s)



£13.1068

3,070 (Deferred)



£13.1118

2,120 (Matching)






d)

Aggregated information


 

Aggregated volume Price

5,190

£13.1093

 

e)

Date of the transaction

2018-02-16

 

f)

Place of the transaction

 

London Stock Exchange (XLON)

 



 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr D Redfern

b)

Position/status

Chief Strategy Officer

c)

Initial notification/

amendment

Initial Notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882

 

 

 

 

b)

Nature of the transaction

The exercise of nil-cost options over Ordinary Shares granted on 11 February 2015 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.

c)

Price(s) and volume(s)


Price(s)

Volume(s)



£0.0000

10,258 (Deferred)



£0.0000

7,078 (Matching)






d)

Aggregated information


Aggregated volume Price

17,336

£0.0000

e)

Date of the transaction

2018-02-16

f)

Place of the transaction

 

n/a

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

 

a)

Name

Mr D Redfern

 

b)

Position/status

Chief Strategy Officer

 

c)

Initial notification/

amendment

Initial Notification

 

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

Name

GlaxoSmithKline plc

 

b)

LEI

5493000HZTVUYLO1D793

 

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

 

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882

 

 

 

 

 

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 16 February 2018 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.

 

c)

Price(s) and volume(s)


Price(s)

Volume(s)



£13.1800

4,822 (Deferred)



£13.1800

3,328 (Matching)






d)

Aggregated information


 

Aggregated volume Price

8,150

£13.1800

 

e)

Date of the transaction

2018-02-16

 

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms C Thomas

b)

Position/status

SVP, Human Resources

c)

Initial notification/

amendment

Initial Notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882

 

 

 

 

b)

Nature of the transaction

The exercise of nil-cost options over Ordinary Shares granted on 11 February 2015 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.

c)

Price(s) and volume(s)


Price(s)

Volume(s)



£0.0000

13,805 (Deferred)



£0.0000

9,525 (Matching)






d)

Aggregated information


Aggregated volume Price

23,330

£0.0000

e)

Date of the transaction

2018-02-16

f)

Place of the transaction

 

n/a

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms C Thomas

b)

Position/status

SVP, Human Resources

c)

Initial notification/

amendment

Initial Notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882

 

 

 

 

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 16 February 2018 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.

c)

Price(s) and volume(s)


Price(s)

Volume(s)



£13.1180

6,489 (Deferred)



£13.1180

4,478 (Matching)






d)

Aggregated information


Aggregated volume Price

10,967

£13.1180

e)

Date of the transaction

2018-02-16

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr P Thomson

b)

Position/status

President, Global Affairs

c)

Initial notification/

amendment

Initial Notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882

 

 

 

 

b)

Nature of the transaction

The exercise of nil-cost options over Ordinary Shares granted on 11 February 2015 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.

c)

Price(s) and volume(s)


Price(s)

Volume(s)



£0.0000

4,689 (Deferred)



£0.0000

3,235 (Matching)






d)

Aggregated information


Aggregated volume Price

7,924

£0.0000

e)

Date of the transaction

2018-02-19

f)

Place of the transaction

 

n/a

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr P Thomson

b)

Position/status

President, Global Affairs

c)

Initial notification/

amendment

Initial Notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882

 

 

 

 

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 19 February 2018 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.

c)

Price(s) and volume(s)


Price(s)

Volume(s)



£13.1240

2,204 (Deferred)



£13.1240

1,521 (Matching)






d)

Aggregated information


Aggregated volume Price

3,725

£13.1240

e)

Date of the transaction

2018-02-19

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr P Vallance

b)

Position/status

Outgoing President, R&D

c)

Initial notification/

amendment

Initial Notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882

 

 

 

 

b)

Nature of the transaction

The exercise of nil-cost options over Ordinary Shares granted on 11 February 2015 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.

c)

Price(s) and volume(s)


Price(s)

Volume(s)



£0.0000

20,322 (Deferred)



£0.0000

14,022 (Matching)






d)

Aggregated information


Aggregated volume Price

34,344

£0.0000

e)

Date of the transaction

2018-02-19

f)

Place of the transaction

 

n/a

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr P Vallance

b)

Position/status

Outgoing President, R&D

c)

Initial notification/

amendment

Initial Notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882

 

 

 

 

b)

Nature of the transaction

The sale of Ordinary Shares following the exercise of options on 19 February 2018 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.

c)

Price(s) and volume(s)


Price(s)

Volume(s)



£13.1760

20,322 (Deferred)



£13.1760

14,022 (Matching)






d)

Aggregated information


Aggregated volume Price

34,344

£13.1180

e)

Date of the transaction

2018-02-19

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

 

 

 

 

 

 

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHXBLFLVLFFBBL

a d v e r t i s e m e n t